Nuclear p63 expression in osteoblastic tumors

Michael E. Kallen, Melinda E. Sanders, Adriana L. Gonzalez, Jennifer O. Black, Vicki L. Keedy, Kenneth R. Hande, Kelly Cornett Homlar, Jennifer L. Halpern, Ginger E. Holt, Herbert S. Schwartz, Cheryl M. Coffin, Justin M.M. Cates

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Expression of the p63 tumor suppressor protein has been reported in the mononuclear stromal cells of giant cell tumor of the bone, which may represent osteoblast-precursor cells. Only a limited number of osteoblastic tumors have been studied for p63 expression thus far. We therefore examined whether p63 may serve as a marker for osteoblastic differentiation in osteosarcomas or as a differential diagnostic marker to distinguish osteoblastoma from osteosarcoma. Immunohistochemical stains for p63 were performed on a tissue microarray containing 71 chemotherapy naïve biopsy samples of osteosarcoma, 21 whole sections of osteosarcoma, and 8 osteoblastomas. Nuclear p63 was detected in seven of eight osteoblastomas but was restricted to stromal cells within primitive, immature-appearing areas of osteoid deposition. Although only 7 of 71 (10 %) biopsy samples of osteosarcoma represented on the tissue microarray were positive for p63, 7 of 21 (33 %) osteosarcomas were positive when whole tissue sections were evaluated. Although p63 is detected in most osteoblastomas, it is also observed in a significant subset of osteosarcomas, severely limiting its utility in distinguishing between benign and malignant osteoblastic tumors. The relatively low prevalence of p63 expression in osteosarcoma would also seem to preclude its use as a marker of osteoblastic differentiation in skeletal sarcomas.

Original languageEnglish (US)
Pages (from-to)1639-1644
Number of pages6
JournalTumor Biology
Volume33
Issue number5
DOIs
StatePublished - Oct 1 2012

Fingerprint

Osteosarcoma
Osteoblastoma
Neoplasms
Differentiation Antigens
Stromal Cells
Giant Cell Tumor of Bone
Tumor Suppressor Proteins
Biopsy
Osteoblasts
Sarcoma
Coloring Agents
Drug Therapy

Keywords

  • Osteoblastoma
  • Osteosarcoma
  • Tissue microarray
  • p63

ASJC Scopus subject areas

  • Cancer Research

Cite this

Kallen, M. E., Sanders, M. E., Gonzalez, A. L., Black, J. O., Keedy, V. L., Hande, K. R., ... Cates, J. M. M. (2012). Nuclear p63 expression in osteoblastic tumors. Tumor Biology, 33(5), 1639-1644. https://doi.org/10.1007/s13277-012-0419-y

Nuclear p63 expression in osteoblastic tumors. / Kallen, Michael E.; Sanders, Melinda E.; Gonzalez, Adriana L.; Black, Jennifer O.; Keedy, Vicki L.; Hande, Kenneth R.; Homlar, Kelly Cornett; Halpern, Jennifer L.; Holt, Ginger E.; Schwartz, Herbert S.; Coffin, Cheryl M.; Cates, Justin M.M.

In: Tumor Biology, Vol. 33, No. 5, 01.10.2012, p. 1639-1644.

Research output: Contribution to journalArticle

Kallen, ME, Sanders, ME, Gonzalez, AL, Black, JO, Keedy, VL, Hande, KR, Homlar, KC, Halpern, JL, Holt, GE, Schwartz, HS, Coffin, CM & Cates, JMM 2012, 'Nuclear p63 expression in osteoblastic tumors', Tumor Biology, vol. 33, no. 5, pp. 1639-1644. https://doi.org/10.1007/s13277-012-0419-y
Kallen ME, Sanders ME, Gonzalez AL, Black JO, Keedy VL, Hande KR et al. Nuclear p63 expression in osteoblastic tumors. Tumor Biology. 2012 Oct 1;33(5):1639-1644. https://doi.org/10.1007/s13277-012-0419-y
Kallen, Michael E. ; Sanders, Melinda E. ; Gonzalez, Adriana L. ; Black, Jennifer O. ; Keedy, Vicki L. ; Hande, Kenneth R. ; Homlar, Kelly Cornett ; Halpern, Jennifer L. ; Holt, Ginger E. ; Schwartz, Herbert S. ; Coffin, Cheryl M. ; Cates, Justin M.M. / Nuclear p63 expression in osteoblastic tumors. In: Tumor Biology. 2012 ; Vol. 33, No. 5. pp. 1639-1644.
@article{3019216337d8440f89f2a1e541b278d5,
title = "Nuclear p63 expression in osteoblastic tumors",
abstract = "Expression of the p63 tumor suppressor protein has been reported in the mononuclear stromal cells of giant cell tumor of the bone, which may represent osteoblast-precursor cells. Only a limited number of osteoblastic tumors have been studied for p63 expression thus far. We therefore examined whether p63 may serve as a marker for osteoblastic differentiation in osteosarcomas or as a differential diagnostic marker to distinguish osteoblastoma from osteosarcoma. Immunohistochemical stains for p63 were performed on a tissue microarray containing 71 chemotherapy na{\"i}ve biopsy samples of osteosarcoma, 21 whole sections of osteosarcoma, and 8 osteoblastomas. Nuclear p63 was detected in seven of eight osteoblastomas but was restricted to stromal cells within primitive, immature-appearing areas of osteoid deposition. Although only 7 of 71 (10 {\%}) biopsy samples of osteosarcoma represented on the tissue microarray were positive for p63, 7 of 21 (33 {\%}) osteosarcomas were positive when whole tissue sections were evaluated. Although p63 is detected in most osteoblastomas, it is also observed in a significant subset of osteosarcomas, severely limiting its utility in distinguishing between benign and malignant osteoblastic tumors. The relatively low prevalence of p63 expression in osteosarcoma would also seem to preclude its use as a marker of osteoblastic differentiation in skeletal sarcomas.",
keywords = "Osteoblastoma, Osteosarcoma, Tissue microarray, p63",
author = "Kallen, {Michael E.} and Sanders, {Melinda E.} and Gonzalez, {Adriana L.} and Black, {Jennifer O.} and Keedy, {Vicki L.} and Hande, {Kenneth R.} and Homlar, {Kelly Cornett} and Halpern, {Jennifer L.} and Holt, {Ginger E.} and Schwartz, {Herbert S.} and Coffin, {Cheryl M.} and Cates, {Justin M.M.}",
year = "2012",
month = "10",
day = "1",
doi = "10.1007/s13277-012-0419-y",
language = "English (US)",
volume = "33",
pages = "1639--1644",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "5",

}

TY - JOUR

T1 - Nuclear p63 expression in osteoblastic tumors

AU - Kallen, Michael E.

AU - Sanders, Melinda E.

AU - Gonzalez, Adriana L.

AU - Black, Jennifer O.

AU - Keedy, Vicki L.

AU - Hande, Kenneth R.

AU - Homlar, Kelly Cornett

AU - Halpern, Jennifer L.

AU - Holt, Ginger E.

AU - Schwartz, Herbert S.

AU - Coffin, Cheryl M.

AU - Cates, Justin M.M.

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Expression of the p63 tumor suppressor protein has been reported in the mononuclear stromal cells of giant cell tumor of the bone, which may represent osteoblast-precursor cells. Only a limited number of osteoblastic tumors have been studied for p63 expression thus far. We therefore examined whether p63 may serve as a marker for osteoblastic differentiation in osteosarcomas or as a differential diagnostic marker to distinguish osteoblastoma from osteosarcoma. Immunohistochemical stains for p63 were performed on a tissue microarray containing 71 chemotherapy naïve biopsy samples of osteosarcoma, 21 whole sections of osteosarcoma, and 8 osteoblastomas. Nuclear p63 was detected in seven of eight osteoblastomas but was restricted to stromal cells within primitive, immature-appearing areas of osteoid deposition. Although only 7 of 71 (10 %) biopsy samples of osteosarcoma represented on the tissue microarray were positive for p63, 7 of 21 (33 %) osteosarcomas were positive when whole tissue sections were evaluated. Although p63 is detected in most osteoblastomas, it is also observed in a significant subset of osteosarcomas, severely limiting its utility in distinguishing between benign and malignant osteoblastic tumors. The relatively low prevalence of p63 expression in osteosarcoma would also seem to preclude its use as a marker of osteoblastic differentiation in skeletal sarcomas.

AB - Expression of the p63 tumor suppressor protein has been reported in the mononuclear stromal cells of giant cell tumor of the bone, which may represent osteoblast-precursor cells. Only a limited number of osteoblastic tumors have been studied for p63 expression thus far. We therefore examined whether p63 may serve as a marker for osteoblastic differentiation in osteosarcomas or as a differential diagnostic marker to distinguish osteoblastoma from osteosarcoma. Immunohistochemical stains for p63 were performed on a tissue microarray containing 71 chemotherapy naïve biopsy samples of osteosarcoma, 21 whole sections of osteosarcoma, and 8 osteoblastomas. Nuclear p63 was detected in seven of eight osteoblastomas but was restricted to stromal cells within primitive, immature-appearing areas of osteoid deposition. Although only 7 of 71 (10 %) biopsy samples of osteosarcoma represented on the tissue microarray were positive for p63, 7 of 21 (33 %) osteosarcomas were positive when whole tissue sections were evaluated. Although p63 is detected in most osteoblastomas, it is also observed in a significant subset of osteosarcomas, severely limiting its utility in distinguishing between benign and malignant osteoblastic tumors. The relatively low prevalence of p63 expression in osteosarcoma would also seem to preclude its use as a marker of osteoblastic differentiation in skeletal sarcomas.

KW - Osteoblastoma

KW - Osteosarcoma

KW - Tissue microarray

KW - p63

UR - http://www.scopus.com/inward/record.url?scp=84868153096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868153096&partnerID=8YFLogxK

U2 - 10.1007/s13277-012-0419-y

DO - 10.1007/s13277-012-0419-y

M3 - Article

C2 - 22623071

AN - SCOPUS:84868153096

VL - 33

SP - 1639

EP - 1644

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 5

ER -